Custom Health (CHLT) Q2 2026 earnings summary

Executive summary

• Achieved quarterly revenue of US $7.4 million for Q2-2026, a 70% increase year-over-year, reflecting the acquisition of InnovativeRx and strong organic growth.

• Proforma revenue for the combined entity for Q2-2026 was US $14.3 million, including full quarter earnings from InnovativeRx.

• Completed Toronto Stock Exchange listing and advanced integration of InnovativeRx, expanding U.S. pharmacy capabilities.

• Announced binding agreements to acquire Evergreen Pharmacy and Spencer Health Solutions, expected to significantly expand specialty pharmacy and in-home technology capabilities.

Financial highlights

• Quarterly revenue from continuing operations reached US $7.4 million, up 70% from US $4.3 million in Q2-2025.

• Gross profit increased 43% to US $2.9 million, with gross margin at 39.3% versus 46.7% a year ago.

• Adjusted EBITDA loss was US $3.3 million, compared to a loss of US $3.0 million in Q2-2025.

• IFRS net loss from continuing operations was US $33.4 million, primarily due to a US $22.4 million one-time, non-cash listing expense related to the reverse takeover.

• Net loss per share was $1.29, compared to $0.36 in Q2-2025.

Outlook and guidance

• Upon closing and integration of Evergreen and Spencer acquisitions, annualized revenue run-rate is expected to exceed US $130 million by end of 2026.

• Positive EBITDA is targeted for 2027 as the company continues its strategy of accretive acquisitions.